154 related articles for article (PubMed ID: 36055298)
1. Immune checkpoint inhibition in sarcomas: time to be histology-specific?
Napolitano A; Huang PH; Jones RL; Tu C
Lancet Oncol; 2022 Sep; 23(9):1111-1112. PubMed ID: 36055298
[No Abstract] [Full Text] [Related]
2. Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?
Assi T; Cesne AL; Mir O
Immunotherapy; 2021 Feb; 13(2):91-93. PubMed ID: 33291976
[No Abstract] [Full Text] [Related]
3. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
4. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
5. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.
Scheinberg T; Lomax A; Tattersall M; Thomas D; McCowage G; Sullivan M; Karim R; Luk PP; Mahar A; Bonar F; Bhadri VA
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1327. PubMed ID: 33314769
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
7. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
9. Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2020 Jan; 20(1):5-8. PubMed ID: 31859537
[No Abstract] [Full Text] [Related]
10. Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas.
Ray A; Huh WW
Curr Oncol Rep; 2012 Aug; 14(4):311-9. PubMed ID: 22535507
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of immunotherapy for the treatment of sarcoma.
Klemen ND; Kelly CM; Bartlett EK
J Surg Oncol; 2021 Mar; 123(3):730-738. PubMed ID: 33259653
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
14. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
15. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V
J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and Biomarkers in Sarcoma.
Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional.
Borgatti A; Dickerson EB; Lawrence J
Vet Comp Oncol; 2020 Mar; 18(1):9-24. PubMed ID: 31749286
[TBL] [Abstract][Full Text] [Related]
19. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
[TBL] [Abstract][Full Text] [Related]
20. Soft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs?
Blay JY; Cassier PA; Ray-Coquard I
Eur J Cancer; 2011 Sep; 47 Suppl 3():S385-8. PubMed ID: 21944026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
